THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this circular, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this circular.

If you are in any doubt as to any aspect of this circular or as to the action to be taken, you should consult a stockbroker or other registered dealer in securities, bank manager, solicitor, professional accountant, or other professional adviser.

If you have sold or transferred all your shares in Good Fellow Healthcare Holdings Limited (the "Company"), you should at once hand this circular and the accompanying form of proxy to the purchaser or transferee or to the bank, stockbroker or other agent through whom the sale or transfer was effected for transmission to the purchaser or the transferee.



金威医疗集团有限公司

Good Fellow Healthcare Holdings Limited

(formerly known as Hua Xia Healthcare Holdings Limited 華夏醫療集團有限公司*)

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 8143)

(1) PROPOSED GENERAL MANDATES TO ISSUE AND REPURCHASE SHARES;

(2) PROPOSED RE-ELECTION OF RETIRING DIRECTORS
AND CONTINUOUS APPOINTMENT OF
AN INDEPENDENT NON-EXECUTIVE DIRECTOR
WHO HAS SERVED FOR MORE THAN NINE YEARS;
AND

(3) NOTICE OF ANNUAL GENERAL MEETING

A notice convening the annual general meeting (the "AGM") of the Company to be held at 3/F, Shun Tak Centre, Merchant Tower, 200 Connaught Road, Central, Hong Kong on Friday, 9 August 2019 at 11:00 a.m. is set out on pages 17 to 21 of this circular. A form of proxy for the AGM is enclosed with this circular. Whether or not you are able to attend the AGM, you are requested to complete the form of proxy in accordance with the instruction printed thereon and return the same to the Company's branch share registrar and transfer office in Hong Kong, Tricor Tengis Limited, at Level 22, Hopewell Centre, 183 Queen's Road East, Hong Kong (which will be relocated to Level 54, Hopewell centre, 183 Queen's Road East, Hong Kong with effect from 11 July 2019) as soon as possible but in any event not less than 48 hours before the time appointed for the holding of the AGM (i.e. no later than 11:00 a.m. on Wednesday, 7 August 2019 (Hong Kong time)) or any adjournment of such meeting. Completion and return of the enclosed form of proxy will not preclude you from attending and voting in person at such meeting or any adjournment meeting should you so wish.

This circular will remain on the "Latest Company Announcements" page of the GEM website at www.hkgem.com for at least 7 days from the date of its posting and the website of the Company at www.gf-healthcare.com.

28 June 2019

CHARACTERISTICS OF GEM

GEM has been positioned as a market designed to accommodate small and midsized companies to which a higher investment risk may be attached than other companies listed on the Stock Exchange. Prospective investors should be aware of the potential risks of investing in such companies and should make the decision to invest only after due and careful consideration.

Given the companies listed on GEM are generally small and mid-sized companies, there is a risk that securities traded on GEM may be more susceptible to high market volatility than securities traded on the Main Board and no assurance is given that there will be a liquid market in the securities traded on GEM.

CONTENTS

	Page
DEFINITIONS	1
LETTER FROM THE BOARD	
INTRODUCTION	3
(1) PROPOSED GENERAL MANDATE TO ISSUE AND	
REPURCHASE SHARES	4
(2) RE-ELECTION OF RETIRING DIRECTORS	
AND CONTINUOUS APPOINTMENT OF	
MS. WONG KA WAI, JEANNE	6
(3) ANNUAL GENERAL MEETING	7
CLOSURE OF REGISTER OF MEMBERS	7
GEM LISTING RULES REQUIREMENT FOR VOTING	7
SHAREHOLDERS ABSTAIN FROM VOTING	7
RESPONSIBILITY STATEMENT	8
RECOMMENDATIONS	8
GENERAL	8
APPENDIX I - EXPLANATORY STATEMENT	9
APPENDIX II - DETAILS OF THE RETIRING DIRECTORS PROPOSED	
TO BE RE-ELECTED	15
NOTICE OF ANNUAL GENERAL MEETING	17

DEFINITIONS

In this circular, the following expression shall have the following meanings unless the context otherwise requires:

"acting in concert" has the same meaning ascribed to it under the Takeovers

Code

"AGM" the annual general meeting of the Company to be held at

3/F, Shun Tak Centre, Merchant Tower, 200 Connaught Road, Central, Hong Kong on Friday, 9 August 2019 at

11:00 a.m.

"Articles of Association" or

"Articles"

articles of association of the Company, as amended from

time to time

"Board" the board of Directors

"close associates" have the same meaning as prescribed in the GEM Listing

Rules

"Company" Good Fellow Healthcare Holdings Limited, a company

incorporated in the Cayman Islands with limited liability, the issued Shares of which are listed on GEM (stock code:

8143)

"Companies Law" the companies law, Cap. 22 (Law 3 of 1961, as consolidated

and revised) of the Cayman Islands

"Director(s)" the director(s) of the Company

"GEM" GEM operated by the Stock Exchange

"GEM Listing Rules" the Rules Governing the Listing of Securities on GEM

"General Mandate" the general mandate proposed to be granted to the Directors

at the AGM to allot, issue and deal with new Shares not exceeding 20% of the total number of issued Shares as at the date of the AGM which is to be extended by the number of Shares purchased pursuant to the Repurchase Mandate

"Group" the Company and its subsidiaries

DEFINITIONS

"Hong Kong" the Hong Kong Special Administrative Region of the PRC

"Latest Practicable Date" 24 June 2019, being the latest practicable date prior to the

printing of this circular for ascertaining certain information

contained herein

"Main Board" the stock market operated by the Stock Exchange prior to

the establishment of GEM (excluding the options market) and which stock market continues to be operated by the Stock Exchange in parallel with GEM. For the avoidance of

doubt, the Main Board excludes GEM

"PRC" the People's Republic of China, which for the purpose

of this circular excludes Hong Kong, the Macau Special

Administrative Region of the PRC and Taiwan

"Repurchase Mandate" a general and unconditional mandate to be granted to

the Directors at the AGM to exercise all powers of the Company to repurchase Shares up to a maximum of 10% of the total number of issued Shares as at the date of passing

of the relevant resolution granting such mandate

"SFO" the Securities and Futures Ordinance (Chapter 571 of the

Laws of Hong Kong)

"Shareholder(s)" holder(s) of the Shares

"Shares" ordinary shares of HK\$0.01 each in the issued share capital

of the Company

"Stock Exchange" The Stock Exchange of Hong Kong Limited

"Takeovers Code" the Hong Kong Code on Takeovers and Mergers

"HK\$" Hong Kong dollars, the lawful currency of Hong Kong

"%" per cent.



金威医疗集团有限公司

Good Fellow Healthcare Holdings Limited

(formerly known as Hua Xia Healthcare Holdings Limited 華夏醫療集團有限公司*)
(incorporated in the Cayman Islands with limited liability)

(Stock Code: 8143)

Executive Directors:

Mr. Ng Chi Lung (Chairman)

Dr. Jiang Tao (Chief Executive Officer)

Mr. Zheng Gang

Independent non-executive Directors:

Ms. Wong Ka Wai, Jeanne

Dr. Lam Huen Sum

Mr. Liu Chenli

Registered office:

P.O. Box 10008

Willow House

Cricket Square

Grand Cayman KY1-1001

Cayman Islands

Head office and principal place of

business in Hong Kong:

19th Floor, New Wing

101 King's Road

Hong Kong

28 June 2019

To Shareholders of the Company, and for information only, holder(s) of options and convertible preference shares

Dear Sir or Madam,

(1) PROPOSED GENERAL MANDATES TO ISSUE AND REPURCHASE SHARES;

(2) PROPOSED RE-ELECTION OF RETIRING DIRECTORS AND CONTINUOUS APPOINTMENT OF AN INDEPENDENT NON-EXECUTIVE DIRECTOR WHO HAS SERVED FOR MORE THAN NINE YEARS; AND

(3) NOTICE OF ANNUAL GENERAL MEETING

INTRODUCTION

The purpose of this circular is to provide you with information regarding certain resolutions to be proposed at the forthcoming AGM of the Company to be held on Friday, 9 August 2019 at 11:00 a.m., including but not limited to (i) ordinary resolutions relating to the grant of General Mandate and Repurchase Mandate to the Directors for the issue and repurchase of its Shares; and (ii) ordinary resolution relating to the re-election of the retiring Directors and continuous appointment of Ms. Wong Ka Wai, Jeanne as independent non-executive Director.

^{*} For identification purpose only

(1) PROPOSED GENERAL MANDATE TO ISSUE AND REPURCHASE SHARES

The existing general mandate granted to the Directors to allot and issue new Shares and to repurchase Shares at the annual general meeting of the Company held on 10 August 2018 will lapse at the conclusion of the AGM.

At the AGM, ordinary resolutions will be proposed to the Shareholders (a) approving the grant of the General Mandate to the Directors to allot, issue and otherwise deal in the new Shares not exceeding 20% of the total number of issued Shares as at the date of passing such resolution; (b) approving the grant of the Repurchase Mandate to the Directors to repurchase, inter alia, Shares, the number of which does not exceed 10% of the total number of issued Shares as at the date of passing such resolution; and (c) adding to the total number of Shares which may be allotted, issued or dealt in under the General Mandate the number of Shares repurchased by the Company under the Repurchase Mandate.

The General Mandate

Under the General Mandate, the Directors will be given a general mandate to allot, issue and deal in the new Shares representing not more than 20% of the total number of issued Shares as at the date of passing such resolution.

As at the Latest Practicable Date, the Company had an aggregate of 2,818,249,944 Shares in issue. Subject to the passing of the ordinary resolution for the approval of the General Mandate and assuming that no Shares will be issued or repurchased by the Company between the Latest Practicable Date and the date of the AGM, the Company would be allowed under the General Mandate to allot, issue and deal in up to a maximum of 563,649,988 new Shares.

The Repurchase Mandate

It is also proposed that the Repurchase Mandate be granted to the Directors.

Under the Repurchase Mandate, the Directors will be given a repurchase mandate to repurchase Shares representing not more than 10% of the total number of issued Shares as at the date of passing such resolution, on GEM or on any stock exchange recognised by the Securities and Futures Commission of Hong Kong and the Stock Exchange.

As at the Latest Practicable Date, the Company had an aggregate of 2,818,249,944 Shares in issue. Subject to the passing of the ordinary resolution for the approval of the Repurchase Mandate and assuming that no Shares will be issued or repurchased by the Company between the Latest Practicable Date and the date of the AGM, the Company would be allowed under the Repurchase Mandate to repurchase up to a maximum of 281,824,994 Shares.

The explanatory statement required by the GEM Listing Rules to be sent to the Shareholders in connection with the proposed Repurchase Mandate is set out on pages 9 to 14 of this circular.

The Directors wish to state that they have no present intention to repurchase any Shares.

Extension of the General Mandate

Subject to the approval of the Repurchase Mandate, another ordinary resolution will be proposed at the AGM to add to the limit under the General Mandate the number of Shares repurchased by the Company pursuant to the Repurchase Mandate.

Effectiveness of General Mandate and Repurchase Mandate

The General Mandate and the Repurchase Mandate shall be effective until whichever is the earliest of:

- (a) the conclusion of the next annual general meeting of the Company; or
- (b) the expiration of the period within which the next annual general meeting of the company is required by the Articles of Association, or any applicable law of the Cayman Islands to be held; or
- (c) the passing of an ordinary resolution by the Shareholders in a general meeting revoking or varying the authority given to the Directors.

(2) RE-ELECTION OF RETIRING DIRECTORS AND CONTINUOUS APPOINTMENT OF MS. WONG KA WAI, JEANNE

According to Article 86(3) of the Articles of Association, the Board shall have the power from time to time and at any time to appoint any person as Director either to fill a casual vacancy or as an additional Director. Any Director so appointed should be subject to election by Shareholders at the first general meeting after the appointment and shall then be eligible for re-election.

According to Article 87(1) of the Articles of Association, at each annual general meeting, one-third of the Directors for the time being (or, if their numbers is not a multiple of three, then the number nearest to but not less than one-third) shall retire from office by rotation, provided that every Director (including those appointed for a specific term) shall be subject to at least once in every three years. A retiring Director shall be eligible for re-election.

In accordance with Article 87(1) of the Articles of Association, Dr. Jiang Tao and Ms. Wong Ka Wai, Jeanne shall retire from their offices at the AGM and, being eligible, will offer themselves for re-election.

According to code provision A.4.3 of the Corporate Governance Code as set out in Appendix 15 of the GEM Listing Rules, if an independent non-executive director serves more than nine years, any further appointment of such independent non-executive director should be subject to a separate resolution to be approved by Shareholders. Ms. Wong Ka Wai, Jeanne ("Ms. Wong") has been appointed as an independent non-executive Director for more than ten years. The Company has received from Ms. Wong a confirmation of independence according to Rule 5.09 of the GEM Listing Rules. Ms. Wong has not engaged in any executive management of the Group. Taking into consideration of her independent scope of work in the past years, the Directors consider Ms. Wong to be independent under the GEM Listing Rules despite the fact that she has served the Company for more than ten years. With her finance and accounting background, skills and experience for over 25 years, as well as her professional qualification, Ms. Wong has demonstrated the ability to provide valuable insight to the Group and her presence in the Board contributes to the diversity of the Board. The Board believes that Ms. Wong is able to continue to fulfill her role as an independent non-executive Director and her continued tenure brings considerable stability to the Board and thus recommends her for re-election at the AGM.

At the AGM, ordinary resolutions will be proposed to re-elect each of Dr. Jiang Tao and Ms. Wong Ka Wai, Jeanne as executive/independent non-executive Director (as the case may be).

Details of the Directors who are proposed to be re-elected at the AGM are set out in Appendix II to this circular.

(3) ANNUAL GENERAL MEETING

A notice convening the AGM of the Company to be held at 3/F, Shun Tak Centre, Merchant Tower, 200 Connaught Road, Central, Hong Kong on Friday, 9 August 2019 at 11:00 a.m. is set out in this circular. A form of proxy for the AGM is enclosed with this circular. Whether or not you are able to attend the AGM in person, please complete and return the form of proxy in accordance with the instructions printed thereon to the Company's branch share registrar and transfer office in Hong Kong, Tricor Tengis Limited, at Level 22, Hopewell Centre, 183 Queen's Road East, Hong Kong (which will be relocated to Level 54, Hopewell centre, 183 Queen's Road East, Hong Kong with effect from 11 July 2019) as soon as possible and in any event not less than 48 hours before the time appointed for holding of the AGM (i.e. no later than 11:00 a.m. on Wednesday, 7 August 2019 (Hong Kong time)) or any adjournment of such meeting. Completion and return of the form of proxy will not preclude you from attending and voting at the AGM or any adjourned meeting (as the case may be) should you so wish.

CLOSURE OF REGISTER OF MEMBERS

The AGM will be held on Friday, 9 August 2019. For determining the entitlement to attend and vote at the AGM, the register of members of the Company will be closed from Tuesday, 6 August 2019 to Friday, 9 August 2019 (both dates inclusive) during which period no transfer of Shares will be effected. In order to qualify for attending and voting at the AGM, unregistered holders of the Shares should ensure that all share transfer forms accompanied by the relevant share certificates must be lodged with the Company's branch share registrar and transfer office in Hong Kong, Tricor Tengis Limited, at Level 22, Hopewell Centre, 183 Queen's Road East, Hong Kong (which will be relocated to Level 54, Hopewell centre, 183 Queen's Road East, Hong Kong with effect from 11 July 2019) for registration not later than 4:30 p.m. on Monday, 5 August 2019.

GEM LISTING RULES REQUIREMENT FOR VOTING

Pursuant to Rule 17.47(4) of the GEM Listing Rules, vote of shareholders at a general meeting must be taken by poll. Accordingly, all resolutions will be put to vote by way of poll at the AGM. An announcement on the poll vote results will be made by the Company after the AGM in the manner prescribed under Rule 17.47(5) of the GEM Listing Rules.

SHAREHOLDERS ABSTAIN FROM VOTING

None of the Shareholders is required to abstain from voting in respect of the resolutions to be proposed at the AGM.

RESPONSIBILITY STATEMENT

This circular, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief the information contained in this circular is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this circular misleading.

RECOMMENDATIONS

The Directors consider that (i) the general mandates to the Directors for the issue and repurchase of Shares; and (ii) the re-election of the retiring Directors and continuous appointment of Ms. Wong Ka Wai, Jeanne as an independent non-executive Director are in interests of the Company and its Shareholders as a whole. Accordingly, the Directors recommend all Shareholders to vote in favour of the relevant resolutions to be proposed at the forthcoming AGM.

GENERAL

As at the Latest Practicable Date, to the best of the Directors' knowledge, information and belief, having made all reasonable enquiries, none of the Directors, or the controlling Shareholder or their respective close associates had any interests in a business which competes or may compete with the business of the Group and have any other conflicts of interest with the Group.

Your attention is also drawn to the additional information set out in the Appendices to this circular.

This circular is in English and Chinese. In case of any inconsistency, the English version shall prevail.

By order of the Board

Good Fellow Healthcare Holdings Limited

Ng Chi Lung

Chairman and Executive Director

This is an explanatory statement given to all Shareholders relating to the resolution to be proposed at the AGM authorising the Repurchase Mandate. It contains all the relevant information required pursuant to Rule 13.08 of the GEM Listing Rules which is set out as follows:

1. SHARE CAPITAL

As at the Latest Practicable Date, the issued share capital of the Company comprised 2,818,249,944 Shares of HK\$0.01 each.

Subject to the passing of the resolution in relation to the Repurchase Mandate and on the basis that no Shares are issued or repurchased by the Company prior to the AGM, the Company will be allowed under the Repurchase Mandate to repurchase a maximum of 281,824,994 Shares equivalent to approximately 10% of the total number of issued Shares. The repurchased Shares will be cancelled and the Company's issued share capital will be reduced accordingly by the number of Shares repurchased.

2. EXERCISE OF THE REPURCHASE MANDATE

Exercise in full of the Repurchase Mandate, on the basis of 2,818,249,944 Shares in issue as at the Latest Practicable Date, could result in up to 281,824,994 Shares listed on GEM or on another stock exchange recognised by the Securities and Futures Commission and the Stock Exchange under the Code on Share Buy-backs being repurchased by the Company during the period up to (i) the conclusion of the next annual general meeting of the Company after the AGM; (ii) the expiration of the period within which the next annual general meeting of the Company after the AGM is required by the Articles of Association or the Companies Law or any other applicable laws of the Cayman Islands to be held; or (iii) the revocation, variation or renewal of the repurchase mandate by ordinary resolution of the Shareholders in a general meeting, whichever occurs first.

3. REASONS FOR REPURCHASES

Although the Directors have no present intention to repurchase any Shares, they believe that the Repurchase Mandate will provide the Company the flexibility to make such repurchases when appropriate and is beneficial to the Company and the Shareholders. Such repurchases may, depending on market conditions and funding arrangements at the relevant time, lead to an enhancement of the net asset value of the Company and/or earning per Share.

4. FUNDING OF REPURCHASES

Repurchase of Shares will be funded out of funds legally available for such purpose in accordance with the memorandum of association, the Articles of Association and the applicable laws and regulations of the Cayman Islands.

The Company may not purchase its own securities on GEM for a consideration other than cash or for settlement otherwise than in accordance with the trading rules of the Stock Exchange from time to time.

5. EFFECT OF EXERCISING THE REPURCHASE MANDATE

There might be a material adverse impact on the working capital or the gearing position of the Group as compared with the position disclosed in the audited financial statements for the year ended 31 March 2019, being the date to which the latest published audited financial statements of the Company were made up, in the event that the Repurchase Mandate is exercised in full. However, the Directors do not propose to exercise the Repurchase Mandate to such an extent as it would, in the circumstances, have a material adverse effect on the working capital requirements of the Group or on the gearing positions which in the opinion of the Directors are from time to time appropriate for the Group. The number of Shares to be repurchased on any occasion and the price and other terms upon which the same are repurchased will be decided by the Directors at the relevant time having regard to the circumstances then prevailing.

6. SHARE PRICES

The highest and lowest prices at which Shares have been traded on GEM in each of the past twelve months preceding the Latest Practicable Date were as follows:

	Price per Share		
	Highest	Lowest	
	HK\$	HK\$	
2018			
June	0.127	0.117	
July	0.130	0.103	
August	0.115	0.105	
September	0.128	0.103	
October	0.125	0.102	
November	0.120	0.100	
December	0.110	0.090	
2019			
January	0.110	0.075	
February	0.104	0.076	
March	0.116	0.089	
April	0.130	0.093	
May	0.123	0.075	
June (up to the Latest Practicable Date)	0.115	0.084	

7. UNDERTAKING OF THE DIRECTORS

The Directors have undertaken to the Stock Exchange that they will exercise the power of the Company to make repurchases pursuant to the proposed resolution in accordance with the GEM Listing Rules and the applicable laws of Hong Kong and in accordance with the regulations set out in the memorandum of association, the Articles of Association and also any applicable laws of the Cayman Islands.

None of the Directors nor, to the best of the knowledge and belief of the Directors having made all reasonable enquires, any of the close associates of any of the Directors has any present intention, in the event that the proposed Repurchase Mandate is approved by the Shareholders, to sell Shares to the Company.

As at the Latest Practicable Date, no core connected person (as defined in the GEM Listing Rules) of the Company has notified the Company that he/she has a present intention to sell Shares to the Company nor has he/she undertaken not to sell any of the Shares held by him/her to the Company in the event that the Company is authorised to make repurchases of Shares.

8. THE HONG KONG CODE ON TAKEOVERS AND MERGERS

If as a result of a Share repurchase, a shareholder's proportionate interest in the voting rights of the Company increases, such increase will be treated as an acquisition for the purpose of Rule 32 of the Takeovers Code. Accordingly, a shareholder or group of shareholders acting in concert, could obtain or consolidate control of the Company and become obliged to make a mandatory offer in accordance with Rules 26 and 32 of the Takeovers Code.

As at the Latest Practicable Date, the register of the substantial shareholders maintained by the Company under section 336 of the SFO showed that the following parties had interests in the Shares representing 10% or more of the voting power at any general meeting of the Company:

Name of Shareholder	Number of Shares	Position	Capacity	Approximate percentage of the total issued Shares	Approximate percentage of shareholding if the Repurchase Mandate is exercised in full
Solar Star Global Limited ("Solar Star") (Note 1)	1,581,959,460	Long	Beneficial owner	56.13%	62.37%
Ng Chi Lung (Note 1)	1,581,959,460 59,000,000	Long Long	Corporate interest Personal interest	56.13% 2.09%	62.37% 2.33%
Cheng Wai Yin (Note 2)	1,640,959,460	Long	Interest of spouse	58.23%	64.70%
New Hope International (Hong Kong) Limited ("New Hope International") (Note 3)	343,217,539	Long	Beneficial owner	12.18%	13.53%
Southern Hope Enterprise Co., Ltd.# (南方希望實業有限公司) (Note 3)	343,217,539	Long	Corporate interest	12.18%	13.53%
New Hope Group Co., Ltd.# (新希望集團有限公司) (Note 3)	343,217,539	Long	Corporate interest	12.18%	13.53%

Name of Shareholder	Number of Shares	Position	Capacity	Approximate percentage of the total issued Shares	Approximate percentage of shareholding if the Repurchase Mandate is exercised in full
Tibet Hengye Feng Industrial Co., Ltd.# (西藏恒業峰實業有限公司) (Note 3)	343,217,539	Long	Corporate interest	12.18%	13.53%
Liu Yonghao (Note 3)	343,217,539	Long	Corporate interest	12.18%	13.53%
Liu Chang (Note 3)	343,217,539	Long	Corporate interest	12.18%	13.53%
Li Wei (Note 4)	343,217,539	Long	Interest of spouse	12.18%	13.53%

Notes:

- Solar Star is interested in 1,581,959,460 Shares and 98,500,000 convertible preference shares of the Company. The issued share capital of Solar Star is owned as to 50% by Mr. Ng Chi Lung, 25% by Ms. Ng Si Wing and 25% by Ms. Ng Yin. Mr. Ng Chi Lung is deemed to be interested in the Shares and the convertible preference shares in which Solar Star is interested in under the SFO.
- 2. Ms. Cheng Wai Yin is the spouse of Mr. Ng Chi Lung. Ms. Cheng Wai Yin is deemed to be interested in the Shares and the convertible preference shares in which Mr. Ng Chi Lung is interested in under Part XV of the SFO.
- 3. New Hope International is interested in 343,217,539 Shares. The issued share capital of New Hope International is owned as to 75% by Southern Hope Enterprise Co., Ltd.# which is in turn owned as to 51% by New Hope Group Co., Ltd.# and as to 49% by Tibet Hengye Feng Industrial Co., Ltd.# Both New Hope Group Co., Ltd.# and Tibet Hengye Feng Industrial Co., Ltd.# are owned as to 62.34% by Mr. Liu Yonghao, as to 36.35% by Ms. Liu Chang and as to 1.31% by Ms. Li Wei. Mr. Liu Yonghao and Ms. Liu Chang are deemed to be interested in the Shares in which New Hope International is interested in under the SFO.
- 4. Ms. Li Wei is the spouse of Mr. Liu Yonghao. Ms. Li Wei is deemed to be interested in the Shares in which Mr. Liu Yonghao is interested in under Part XV of the SFO.

On the basis of the current shareholdings of above Shareholders, an exercise of the Repurchase Mandate in full will not result in them becoming obliged to make a mandatory offer under Rule 26 of the Takeovers Code. The Directors have no intention to exercise the Repurchase Mandate to such an extent that will result in a requirement of the above Shareholders, or any other persons to make a general offer under the Takeovers Code. However, the Company may not repurchase Shares which would result in the number of Shares held by the public being reduced to less than 25%.

The GEM Listing Rules prohibit the Company from knowingly purchasing its securities on GEM from a "connected person", that is, a director, chief executive or substantial shareholder of the Company or any of its subsidiaries or their respective close associates.

None of the Directors nor, to the best of their knowledge, having made all reasonable enquiries, any of their close associates have any present intention to sell Shares to the Company or its subsidiaries under the Repurchase Mandate if such is approved by the Shareholders.

No core connected person (as defined in the GEM Listing Rules) of the Company has notified the Company that it has a present intention to sell Shares to the Company or its subsidiaries, or has undertaken not to do so, in the event that the Repurchase Mandate is approved by the Shareholders.

9. SHARE REPURCHASE MADE BY THE COMPANY

No Shares had been repurchased by the Company, whether on GEM or otherwise, in the last six months prior to the Latest Practicable Date.

DETAILS OF THE RETIRING DIRECTORS PROPOSED TO BE RE-ELECTED

Set out below are details of the Directors who are proposed to be re-elected at the AGM:

1. Dr. Jiang Tao

Dr. Jiang Tao ("Dr. Jiang"), aged 63, holds a degree of doctor of audiology from the Arizona School of Health Sciences of AT Still University in the United States and two master's degrees in audiology and in special education from Lamar University of Texas in the United States. He served as senior management in several enterprises in the United States, Canada and the PRC with over 20 years of experience in senior management, consultancy and investment in the PRC, Hong Kong, Canada and the United States. He is currently the life time visiting Professor of the Kunming Normal University, and formerly Assistant Professor of Dalhousie University of Canada, Sichuan University, and Sun Yatsen Medical University. Dr. Jiang was appointed as an executive Director and deputy chief executive of the Company on 3 January 2007 and 26 March 2010 respectively. Dr. Jiang was appointed as the chief executive officer and the chairman of the nomination and corporate governance committee of the Company on 20 April 2015. He was re-designated as a member of the nomination and corporate governance committee of the Company on 21 June 2019.

Dr. Jiang has entered into a letter of appointment with the Company for a term of one year, subject to retirement by rotation and re-election at annual general meetings pursuant to the Articles of Association. Dr. Jiang is entitled to a monthly director's fee of HK\$130,000 which was determined by the remuneration committee of the Company with reference to his duties and responsibilities within the Group, the Group's remuneration policy and the prevailing market condition. He is also entitled to a discretionary bonus for each financial year, which is payable at the Board's discretion and determined with reference to the Group's results and performance for the financial year concerned.

Save as disclosed above, as at the Latest Practicable Date, (i) Dr. Jiang did not have, and was not deemed to have, any interests or short position in any Shares, underlying shares or debentures of the Company and its associated corporations within the meaning of Part XV of SFO; (ii) Dr. Jiang did not have any relationship with other Directors, senior management, substantial Shareholders or controlling Shareholders (within the meaning of the GEM Listing Rules); and (iii) Dr. Jiang did not hold any other directorship in public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years or any other position with the Company and other members of the Group or other major appointments and professional qualifications.

Save as disclosed above, as at the Latest Practicable Date, there was no further information relating to Dr. Jiang that is required to be disclosed pursuant to any of the requirements of Rule 17.50(2)(h) to 17.50(2)(v) of the GEM Listing Rules and there was no other matter in relation to the re-election of Dr. Jiang which needs to be brought to the attention of the Shareholders.

DETAILS OF THE RETIRING DIRECTORS PROPOSED TO BE RE-ELECTED

2. Ms. Wong Ka Wai, Jeanne

Ms. Wong Ka Wai, Jeanne ("Ms. Wong"), aged 55, has over 25 years of experience in finance, accounting, taxation and corporate affairs. She is a member of the Chartered Accountants in Australia and New Zealand, a Certified Public Accountant of the Hong Kong Institute of Certified Public Accountants, a member of the Society of Trust and Estate Practitioner and the Certified Tax Advisor in Hong Kong. Ms. Wong holds a bachelor degree in economics from the University of Sydney, Australia. Ms. Wong is currently the managing director of a private company providing consulting and management services, as well as the chief financial officer of a local law firm and consultant of a local CPA firm. Ms. Wong is currently an independent non-executive director of Phoenitron Holdings Limited (stock code: 8066), a company whose shares are listed on GEM. Ms. Wong was appointed as an independent non-executive Director on 1 November 2007. Ms. Wong is currently the chairlady of the audit committee and the remuneration committee, as well as a member of the nomination and corporate governance committee of the Company.

Ms. Wong has entered into a letter of appointment with the Company for a term of one year, subject to retirement by rotation and re-election at annual general meetings pursuant to the Articles of Association. Ms. Wong is entitled to a monthly director's fee of HK\$10,000 which was determined by the remuneration committee of the Company with reference to her duties and responsibilities within the Group, the Group's remuneration policy and the prevailing market condition. She is also entitled to a discretionary bonus for each financial year, which is payable at the Board's discretion and determined with reference to the Group's results and performance for the financial year concerned.

Save as disclosed above, as at the Latest Practicable Date, (i) Ms. Wong did not have and was not deemed to have, any interests or short position in any Shares, underlying shares or debentures of the Company and its associated corporations within the meaning of Part XV of SFO; (ii) Ms. Wong did not have any relationship with other Directors, senior management, substantial Shareholders or controlling Shareholders (within the meaning of the GEM Listing Rules); and (iii) Ms. Wong did not hold any other directorship in public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years or any other position with the Company and other members of the Group or other major appointments and professional qualifications.

Save as disclosed above, as at the Latest Practicable Date, there was no further information relating to Ms. Wong that is required to be disclosed pursuant to any of the requirements of Rule 17.50(2)(h) to 17.50(2)(v) of the GEM Listing Rules and there was no other matter in relation to the re-election of Ms. Wong which needs to be brought to the attention of the Shareholders.



金威医疗集团有限公司

Good Fellow Healthcare Holdings Limited

(formerly known as Hua Xia Healthcare Holdings Limited 華夏醫療集團有限公司*)
(incorporated in the Cayman Islands with limited liability)

(Stock Code: 8143)

NOTICE IS HEREBY GIVEN THAT the annual general meeting ("**AGM**") of the shareholders ("**Shareholders**") of Good Fellow Healthcare Holdings Limited (the "**Company**") will be held at 3/F, Shun Tak Centre, Merchant Tower, 200 Connaught Road, Central, Hong Kong on Friday, 9 August 2019 at 11:00 a.m. for the following purposes:

- to receive and consider the audited financial statements and the reports of the directors (the "Directors") and auditors of the Company and its subsidiaries for the year ended 31 March 2019;
- 2. (a) to re-elect Dr. Jiang Tao as an executive Director;
 - (b) to re-elect Ms. Wong Ka Wai, Jeanne as an independent non-executive Director; and
 - (c) to authorise the board of Directors (the "**Board**") to fix the remunerations of the Directors;
- 3. to re-appoint HLB Hodgson Impey Cheng Limited as the auditors of the Company and to authorise the Board to fix their remuneration;

^{*} For identification purpose only

As special business, to consider and, if thought fit, pass with or without amendments the following proposed resolutions numbered 4 to 6 as ordinary resolutions:

ORDINARY RESOLUTIONS

4. **THAT**:

- (a) subject to paragraph (c) of this resolution, and pursuant to the Rules Governing the Listing of Securities on GEM ("GEM") of The Stock Exchange of Hong Kong Limited (the "Stock Exchange"), the exercise by the Directors during the Relevant Period (as hereinafter defined) of all the powers of the Company and to allot, issue and deal with additional shares ("Shares") in the capital of the Company and to make or grant offers, agreements and options (including bonds, notes, warrants, debentures and securities convertible into Shares) which might require the exercise of such powers be and the same is hereby generally and unconditionally approved;
- (b) the approval in paragraph (a) of this resolution shall authorise the Directors during the Relevant Period to make or grant offers, agreements and options which might require the exercise of such powers after the end of the Relevant Period;
- (c) the total number of Shares allotted or agreed conditionally or unconditionally to be allotted (whether pursuant to options or otherwise) by the Directors pursuant to the approval in paragraph (a) of this resolution, otherwise than pursuant to (i) a Rights Issue (as defined below); or (ii) the grant or exercise of any option under the any share option scheme of the Company or any other option scheme or similar arrangement of the Company for the time being adopted for the grant or issue to officers and/or employees of the Company and/or any of its subsidiaries of Shares or rights to acquire Shares; or (iii) any scrip dividend or similar arrangement providing for the allotment of Shares in lieu of the whole or part of a dividend on Shares in accordance with the articles of association of the Company in force from time to time; or (iv) any issue of Shares upon the exercise of rights of subscription or conversion under the terms of any existing warrants of the Company or any existing securities of the Company which carry rights to subscribe for are convertible into Shares, shall not exceed the aggregate of:
 - (i) 20% of the total number of issued Shares on the date of the passing of this resolution; and

(ii) (if the Directors are so authorised by a separate ordinary resolution of the shareholders of the Company) the number of Shares repurchased by the Company subsequent to the passing of this resolution (up to a maximum equivalent to 10% of the total number of issued Shares on the date of the passing of this resolution).

and the authority pursuant to paragraph (a) of this resolution shall be limited accordingly; and

- (d) for the purpose of this resolution:
 - (aa) "Relevant Period" means the period from the date of the passing of this resolution until whichever is the earliest of:
 - the conclusion of the next annual general meeting of the Company;
 - (ii) the expiration of the period within which the next annual general meeting of the Company is required by the memorandum of association and articles of association of the Company, or any other applicable laws of the Cayman Islands to be held; and
 - (iii) the passing of an ordinary resolution by the shareholders of the Company in general meeting revoking or varying the authority given to the Directors by this resolution.
 - (bb) "Rights Issue" means an offer of shares in the Company, or offer or issue of warrants, options or other securities giving rights to subscribe for Shares open for a period fixed by the Directors to holders of shares in the Company on the register on a fixed record date in proportion to their holdings of Shares (subject to such exclusion and arrangements as the Directors may deem necessary or expedient in relation to fractional entitlements, or having regard to any restrictions or obligations under the laws of, or the requirements of, or the expenses or delay which may be involved in determining the existence or extent of any restrictions or obligations under the laws of, or the requirements of, any jurisdiction applicable to the Company, or any recognized regulatory body or any stock exchange applicable to the Company).

5. **THAT**:

- (a) subject to paragraph (b) of this resolution, the exercise by the Directors during the Relevant Period (as defined in resolution 4(d)(aa) set out in the notice) of all powers of the Company to purchase its shares on the GEM or any other stock exchange on which the shares of the Company may be listed and recognised by the Securities and Futures Commission of Hong Kong and the Stock Exchange for such purpose, and otherwise in accordance with the rules and regulations of the SFC, the Stock Exchange or any other stock exchange as amended from time to time and all applicable laws in this regard, be and the same is hereby generally and unconditionally approved; and
- (b) the total number of Shares which may be purchased by the Company pursuant to the approval in paragraph (a) of this resolution during the Relevant Period shall not exceed 10% of the total number of issued Shares as at the date of the passing of this resolution and the authority pursuant to paragraph (a) of this resolution shall be limited accordingly.
- 6. **THAT** conditional upon resolutions numbered 4 and 5 of this notice being passed, the general mandate granted to the Directors to allot, issue and deal with additional Shares pursuant to resolution numbered 4 be and is hereby extended by the addition thereto the number of Shares repurchased by the Company under the authority granted to the Directors pursuant to resolution numbered 5.

By order of the Board

Good Fellow Healthcare Holdings Limited

Ng Chi Lung

Chairman and Executive Director

Hong Kong, 28 June 2019

Registered office:
P.O. Box 10008
Willow House
Cricket Square
Grand Cayman KY1-1001
Cayman Islands

Head office and principal place of business in Hong Kong: 19th Floor, New Wing 101 King's Road Hong Kong

Notes:

- 1. A member entitled to attend and vote at the AGM is entitled to appoint one or more proxies to attend and, subject to the provisions of the articles of association of the Company, to vote on his/her/its behalf. A proxy needs not be a member of the Company but must be present in person at the AGM to represent the member. If more than one proxy is so appointed, the appointment shall specify the number and class of Shares in respect of which each such proxy is so appointed.
- 2. A form of proxy for use at the AGM is enclosed with the circular of the Company dated 28 June 2019. Whether or not you intend to attend the AGM in person, you are encouraged to complete and return the enclosed form of proxy in accordance with the instructions printed thereon. Completion and return of a form of proxy will not preclude a member from attending in person and voting at the AGM or any adjournment thereof, should he/she/its so wish.
- 3. In order to be valid, the form of proxy, together with a power of attorney or other authority, if any, under which it is signed, or a certified copy of such power or authority must be deposited at the Company's branch share registrar and transfer office in Hong Kong, Tricor Tengis Limited, at Level 22, Hopewell Centre, 183 Queen's Road East, Hong Kong (which will be relocated to Level 54, Hopewell centre, 183 Queen's Road East, Hong Kong with effect from 11 July 2019), not less than 48 hours before the time appointed for holding the AGM (i.e. no later than 11:00 a.m. on Wednesday, 7 August 2019 (Hong Kong time)) or any adjournment thereof.
- 4. In the case of joint holders of Shares, any one of such holders may vote at the AGM, either personally or by proxy, in respect of such Shares as if he/she/its was solely entitled thereto, but if more than one such joint holders are present at the AGM personally or by proxy, that one of the said persons so present whose name stands first on the register of members of the Company in respect of such Shares shall alone be entitled to vote in respect thereof.
- 5. Any voting at the meeting shall be taken by poll.
- 6. In the case of any inconsistency between the Chinese translation and the English text hereof, the English text shall prevail.
- 7. If a Typhoon Signal No. 8 or above is hoisted or a Black Rainstorm Warning Signal is in force at or at any time after 9:00 a.m. on the date of the meeting, the meeting will be adjourned. The Company will post an announcement on the website of the Stock Exchange (www.hkexnews.hk) and the website of the Company (http://www.gf-healthcare. com.) and to notify shareholders of the date, time and place of the adjourned meeting. The meeting will be held as scheduled when an Amber or a Red Rainstorm Warning Signal is in force. Shareholders should decide on their own whether they would attend the meeting under bad weather conditions bearing in mind their own situations.